Plain-English translation of NCT06215716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help people whose livers have become fatty and scarred due to metabolic problems like obesity, high cholesterol, or diabetes. Participants will receive weekly injections of either the medication at one of two doses or a placebo (a dummy injection with no active drug) while researchers track how well it works and how safe it is over nearly five years.
Fatty liver disease with scarring can progress to severe liver damage, but there are currently very few proven treatments. This trial is testing whether this medication can slow or reverse the scarring process and prevent serious liver complications.
You likely qualify if…
You likely don't qualify if…
You will receive a weekly injection under your skin — either the new medication at one of two strengths or a placebo — and visit the clinic regularly for blood tests and check-ups. Depending on which group you're in, you'll have a repeat liver biopsy at either one or two years to see how your liver has responded. The entire study lasts nearly five years, with follow-up visits for up to a month after you stop receiving injections.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States